title: Technology evaluation: rh lactoferrin, Agennix.
abstract: Agennix is developing recombinant human (rh) lactoferrin, a glycoprotein with antibiotic, anti-inflammatory and immunomodulatory activity, for the potential treatment of cancers, asthma and chronic wounds. rh Lactoferrin is currently undergoing phase II clinical trials.
authors.affiliation: University Hospital of North Norway, Department of Medical Microbiology, Tromso N-9038, Norway. jeanettea@nfh.uit.no
authors.forename: Jeanette H
authors.initials: JH
authors.lastname: Andersen
mesh_terms: D001230:Aspergillus / Q000235:genetics; D001249:Asthma / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007781:Lactoferrin / Q000235:genetics / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000235:genetics / Q000493:pharmacokinetics / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000188:drug therapy*
chemical_list: D011994:Recombinant Proteins; D007781:Lactoferrin